Study of Mirvetuximab Soravtansine vs standard cancer treatments

• Research type

  Research Study

• Full title

  FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor α−positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

• IRAS ID

  198058

• Contact name

  Susana Banerjee

• Contact email

  Susana.Banerjee@rmh.nhs.uk

• Sponsor organisation

  ImmunoGen, Inc.

• Eudract number

  2015-004060-11

• Clinicaltrials.gov Identifier

  NCT02631876

• Duration of Study in the UK

  3 years, 3 months, 30 days

• Research summary

  A study to test mirvetuximab soravtansine (IMGN853) aganist doctor's choice of cancer medicines in women with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

  The purpose of this study is:

  · To compare the experimental drug IMGN853 to standard approved chemotherapy.

  · To find out what effects, both good and/or bad, the study drug may have on these types of cancer.
  
  · To learn if a biomarker test for folate receptor alpha (FRα) protein is helpful in determining which patients are most likely to benefit from IMGN853.

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  17/LO/0064

• Date of REC Opinion

  2 May 2017

• REC opinion

  Further Information Favourable Opinion